Insulin Glargine (Lantus / Basaglar / Toujeo)

1. Overview

Insulin glargine is a long-acting basal insulin analog developed by Hoechst (now Sanofi) and produced by recombinant DNA technology in Escherichia coli. It was designed to provide a prolonged, peakless insulin supply that more closely mimics physiological basal insulin secretion than earlier intermediate-acting formulations such as Neutral Protamine Hagedorn (NPH) insulin [3][13]. Insulin glargine was first approved by the FDA on April 20, 2000, as Lantus (insulin glargine 100 U/mL, designated Gla-100), and has since become one of the most widely prescribed basal insulins worldwide for both type 1 and type 2 diabetes mellitus.

The molecule is a 53-amino acid, two-chain peptide (A-chain: 21 amino acids; B-chain: 32 amino acids) with the molecular formula C267H404N72O78S6 and a molecular weight of approximately 6063 Da [11][13]. It differs from native human insulin by two critical modifications: (1) replacement of asparagine with glycine at position A21 (21A-Gly), which stabilizes the molecule against acid-catalyzed deamidation and aggregation at acidic pH; and (2) addition of two arginine residues to the C-terminus of the B-chain at positions B31 and B32 (30Ba-Arg, 30Bb-Arg). These modifications collectively shift the isoelectric point from approximately pH 5.4 (human insulin) to pH 6.7, rendering the molecule less soluble at physiological pH (~7.4) while maintaining solubility in the acidic formulation buffer (pH 4.0) [11][13][16].

A concentrated formulation, insulin glargine 300 U/mL (Gla-300, marketed as Toujeo), was approved by the FDA on February 25, 2015. By delivering the same molecule in a three-fold higher concentration, the subcutaneous depot volume is reduced by two-thirds, resulting in a smaller surface area, slower dissolution, and an even flatter and more prolonged pharmacokinetic/pharmacodynamic profile extending beyond 24 hours [16][17][22]. Multiple biosimilar products have been approved: Basaglar (insulin glargine, Eli Lilly, 2015), Semglee (insulin glargine-yfgn, Mylan/Biocon, 2021 -- the first interchangeable biosimilar insulin), and Rezvoglar (insulin glargine-aglr, Eli Lilly, 2021) [18][19].

Molecular Weight

~6063 Da

Molecular Formula

C267H404N72O78S6

Structure

53 amino acids (A-chain 21 aa, B-chain 32 aa); two-chain disulfide-linked peptide

Key Modification

21A-Gly substitution; 30Ba-Arg and 30Bb-Arg additions to B-chain C-terminus

Isoelectric Point

pH ~6.7 (vs 5.4 for human insulin)

Duration of Action

~24 h (U-100); >30 h (U-300)

Time to Steady State

2-4 days (U-100); 3-5 days (U-300)

Bioavailability

~70% (subcutaneous)

Routes

Subcutaneous injection (approved)

FDA Status (Lantus)

Approved April 20, 2000 (type 1 and type 2 diabetes)

FDA Status (Toujeo)

Approved February 25, 2015 (type 1 and type 2 diabetes)

FDA Status (Biosimilars)

Basaglar (2015); Semglee (2021, first interchangeable); Rezvoglar (2021)

2. Mechanism of Action

Microprecipitate Formation and Protracted Absorption

The unique pharmacokinetic profile of insulin glargine is entirely dependent on its physicochemical behavior after subcutaneous injection [13][16]. The commercial formulation is a clear, acidic solution at pH 4.0, in which the glargine molecule is fully soluble. Upon injection into subcutaneous tissue, where the pH is approximately 7.4, the molecule encounters a pH environment near its shifted isoelectric point of 6.7. At this near-neutral pH, insulin glargine rapidly becomes insoluble and precipitates to form amorphous microprecipitates within the subcutaneous injection depot [13].

These microprecipitates serve as a sustained-release reservoir. Individual insulin glargine monomers slowly dissolve from the surface of the precipitate particles and are absorbed into the surrounding capillary network. The rate of dissolution is governed by the surface area of the depot -- a critical pharmacokinetic determinant. Because the dissolution process is gradual and relatively constant, the result is a slow, continuous release of insulin glargine monomers into the systemic circulation over approximately 24 hours (for Gla-100) with no pronounced peak, in stark contrast to NPH insulin which has a clear peak at 4-6 hours [13][14][16].

U-100 vs U-300: The Surface Area Principle

For Gla-300 (Toujeo), the same insulin glargine molecule is formulated at three-fold higher concentration (300 U/mL vs 100 U/mL). When the same number of units is injected, the volume delivered is only one-third that of Gla-100. This smaller injection volume produces a more compact subcutaneous depot with reduced surface area relative to the amount of insulin contained within it [16][21][22]. The reduced surface-area-to-volume ratio results in even slower dissolution of monomers from the microprecipitate, translating to:

• A flatter, more extended pharmacokinetic profile (duration >30 hours at steady state)
• Lower within-day pharmacokinetic and pharmacodynamic variability
• Better day-to-day reproducibility of glucose-lowering effect
• More stable glycemic control with reduced risk of hypoglycemia, particularly nocturnal hypoglycemia [4][5][6][8][21]

Metabolic Activity of Glargine and Its Metabolites

After absorption from the subcutaneous depot, insulin glargine undergoes rapid and extensive enzymatic cleavage in the subcutaneous tissue and circulation [11][17]. The basic arginine pair at positions B31 and B32 is cleaved by carboxypeptidase enzymes to yield the primary active metabolite, 21A-Gly-human insulin (designated M1). Further processing removes the threonine at position B30 to form the secondary metabolite, 21A-Gly-des-30B-Thr-human insulin (M2) [11][17].

Critically, the parent insulin glargine molecule is virtually absent in the systemic circulation at therapeutic doses -- M1 is the predominant circulating moiety and is responsible for the vast majority of the metabolic glucose-lowering effect [11]. Both M1 and M2 retain full metabolic activity comparable to human insulin (binding to the insulin receptor, stimulating glucose uptake, suppressing hepatic glucose production, and inhibiting lipolysis) while exhibiting substantially reduced affinity for the insulin-like growth factor 1 receptor (IGF-1R) and correspondingly reduced mitogenic potency relative to parent glargine [11][12]. This metabolic profile is central to the resolution of the cancer safety debate (see Section 3).

Insulin Receptor Signaling

Like native human insulin, the active metabolites of insulin glargine bind to the insulin receptor (IR) on target tissues -- primarily skeletal muscle, adipose tissue, and liver. Receptor binding activates the insulin receptor tyrosine kinase, leading to autophosphorylation and recruitment of insulin receptor substrate (IRS) proteins, which activate two major downstream pathways: the PI3K/Akt pathway (mediating glucose transporter GLUT4 translocation, glycogen synthesis, and suppression of gluconeogenesis) and the Ras/MAPK pathway (mediating cell growth and differentiation). The metabolic effects -- increased peripheral glucose uptake, suppressed hepatic glucose production, inhibited lipolysis, and stimulated protein synthesis -- are equivalent to those of native human insulin [13].

3. Researched Applications

Glycemic Control in Type 2 Diabetes (Strong Evidence -- FDA Approved)

Insulin glargine is approved for basal insulin therapy in adults and children (age 6 and older) with type 1 and type 2 diabetes. The foundational evidence for its superiority over NPH insulin came from the Treat-to-Target trial (n=756), which demonstrated that bedtime insulin glargine added to oral agents achieved comparable HbA1c reduction to NPH insulin (both reaching ~6.96%) but with 25% less nocturnal hypoglycemia (33% vs 44%; p=0.0136). More patients reached HbA1c <7% without documented nocturnal hypoglycemia with glargine (33.2% vs 26.7%; p<0.05) [3].

A comprehensive meta-analysis by Mullins et al. confirmed these advantages across multiple RCTs: insulin glargine reduced the risk of overall symptomatic hypoglycemia by 11% (p=0.0006), nocturnal hypoglycemia by 26% (p<0.0001), severe hypoglycemia by 46%, and severe nocturnal hypoglycemia by 59%, all compared with NPH insulin, while achieving equivalent glycemic control [14]. Early studies in type 1 diabetes also showed reduced nocturnal hypoglycemia with bedtime glargine versus NPH [15].

EDITION Program: Toujeo (U-300) vs Lantus (U-100) (Strong Evidence -- FDA Approved)

The EDITION clinical trial program comprised four pivotal Phase 3 studies (EDITION 1-4) enrolling over 3,500 adults, comparing Gla-300 with Gla-100 across different diabetes populations [4][5][6][7].

EDITION 1 (n=807, T2D on basal-bolus insulin) demonstrated comparable HbA1c reduction with a 21% lower risk of nocturnal confirmed hypoglycemia with Gla-300 (RR 0.79; p=0.0045) [4]. EDITION 2 (n=811, T2D on basal insulin plus oral agents) showed equivalent glycemic control with significantly fewer nocturnal and any-time hypoglycemia events with Gla-300, and less weight gain [5]. EDITION 3 (n=878, insulin-naive T2D) confirmed noninferiority of Gla-300 for HbA1c reduction with lower confirmed hypoglycemia rates, particularly during the critical first 8 weeks of titration [6]. EDITION 4 (n=549, T1D) showed comparable HbA1c reduction with significantly lower nocturnal hypoglycemia during the initial 8-week titration period [7].

A patient-level pooled analysis of EDITION 1, 2, and 3 (n=2,496) confirmed that Gla-300 achieved comparable glycemic control to Gla-100 with a 14% lower rate of any-time confirmed hypoglycemia and a 31% lower rate of nocturnal confirmed hypoglycemia over 6 months [8]. A systematic review and meta-analysis confirmed these benefits, noting that patients switching from Gla-100 to Gla-300 typically require 10-18% higher basal insulin doses to achieve equivalent glycemic control due to the different pharmacokinetic profile [20].

Head-to-Head Comparisons with Second-Generation Basal Insulins

BRIGHT trial (n=929) was the first prospective, head-to-head, randomized trial comparing Gla-300 with insulin degludec 100 U/mL (IDeg-100) in insulin-naive adults with T2D [9]. Over 24 weeks, both insulins improved HbA1c similarly from approximately 8.6% to 7.0% (LS mean difference -0.05%; 95% CI -0.15 to 0.05), demonstrating noninferiority of Gla-300 versus IDeg-100. Importantly, during the active titration period (weeks 0-12), the incidence and rate of confirmed hypoglycemia (both at the <70 mg/dL and <54 mg/dL thresholds) were significantly lower with Gla-300 [9]. Over the full 24-week period, hypoglycemia was comparable between groups.

CONCLUDE trial (n=1,609) compared insulin degludec U200 with Gla-300 in insulin-treated T2D patients at elevated hypoglycemia risk [10]. The primary endpoint -- rate of overall symptomatic hypoglycemia during the maintenance period -- was not significantly lower with degludec versus Gla-300 (RR 0.88; 95% CI 0.73-1.06; p=NS). However, secondary endpoints showed lower rates of nocturnal symptomatic hypoglycemia (RR 0.63; 95% CI 0.48-0.84) and severe hypoglycemia (RR 0.20; 95% CI 0.07-0.57) with degludec, though greater weight gain was observed with degludec [10]. The trial design and generalizability were debated given its open-label nature and the selection of patients at heightened hypoglycemia risk.

Comparison with First-Generation Basal Insulin Analogs

Insulin glargine, insulin detemir (Levemir), and insulin degludec (Tresiba) represent three distinct approaches to prolonging basal insulin action [13]:

• Insulin glargine (Gla-100/Gla-300): Microprecipitate formation at physiological pH in the subcutaneous depot; duration ~24 h (Gla-100) to >30 h (Gla-300)
• Insulin detemir: A C-14 myristic acid fatty acid chain attached at LysB29 enables reversible albumin binding in the subcutaneous space and in circulation, protracting its duration to 12-24 hours. Typically requires twice-daily dosing. Associated with less weight gain than glargine
• Insulin degludec: Forms soluble multi-hexamer chains at the injection site that slowly dissociate into monomers. Ultra-long duration >42 hours with extremely flat profile and the lowest day-to-day variability [24][25]

Systematic reviews confirm no clinically meaningful differences in HbA1c reduction between these agents, though degludec and Gla-300 (second-generation analogs) offer flatter profiles, less within-day variability, and reduced hypoglycemia risk compared with Gla-100 and detemir [13][20].

Cardiovascular and Cancer Safety: The ORIGIN Trial

The ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention) was a landmark multinational RCT that randomized 12,537 adults with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) and high cardiovascular risk to insulin glargine (targeting fasting plasma glucose <95 mg/dL) or standard care, with a 2x2 factorial design also testing omega-3 fatty acids versus placebo [1].

After a median 6.2 years of follow-up, insulin glargine demonstrated:

• Cardiovascular neutrality: The primary composite of cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 1,041 vs 1,013 participants (HR 1.02; 95% CI 0.94-1.11; p=0.63). No excess cardiovascular risk was observed [1]
• Cancer neutrality: Any cancer occurred in 524 vs 529 participants (HR 0.99; 95% CI 0.88-1.12; p=0.91). No increase in any specific cancer type was observed [1]
• Metabolic benefits: New-onset diabetes was reduced by 28% (HR 0.72; 95% CI 0.58-0.91), confirming that early basal insulin therapy can delay diabetes progression
• Trade-offs: Modestly increased weight gain (+1.6 kg vs standard care) and increased rates of hypoglycemia (1.00 vs 0.31 events per 100 person-years for severe hypoglycemia)

The ORIGINALE post-intervention follow-up confirmed that the neutral cardiovascular and cancer effects persisted during more than 2.5 years of post-trial observation, providing robust evidence of long-term safety [2].

Resolution of the Cancer Safety Debate

Between 2009 and 2012, a contentious debate arose regarding a potential association between insulin glargine and increased cancer risk [12][23]. The concern originated from in vitro studies demonstrating that parent insulin glargine has approximately 6-8-fold higher affinity for the IGF-1 receptor compared to human insulin, with associated enhanced mitogenic signaling in cell lines overexpressing IGF-1R. Several observational studies published in 2009 (Hemkens et al., Jonasson et al., Currie et al., Colhoun et al.) produced conflicting results, with some suggesting increased cancer risk with glargine.

The resolution of this debate rested on two pillars [11][12]:

1. Pharmacokinetic evidence: Studies by Bolli et al. (2012) demonstrated that parent insulin glargine is virtually absent in systemic circulation after subcutaneous injection, as it is rapidly and completely converted to metabolites M1 and M2 in the subcutaneous tissue. M1 and M2 have IGF-1R affinity and mitogenic potency comparable to or lower than human insulin, making the in vitro findings of enhanced mitogenicity clinically irrelevant [11]

2. Clinical trial evidence: The ORIGIN trial (n=12,537; median 6.2 years) definitively showed no excess cancer risk with insulin glargine versus standard care (HR 0.99; 95% CI 0.88-1.12) across all cancer types [1]. The ORIGINALE extension confirmed these findings after a total observation period exceeding 8 years [2]. As Owens (2012) concluded, these data "suggest closure" of the glargine-cancer debate [12]

Hypoglycemia Profiles

The hypoglycemia advantage of insulin glargine over NPH insulin is well-established and is attributable to its peakless absorption profile [3][14][15]:

• Glargine vs NPH in T2D: 26% reduction in nocturnal hypoglycemia, 46% reduction in severe hypoglycemia [14]
• Glargine vs NPH in T1D: Significantly reduced nocturnal hypoglycemia with equivalent glycemic control [15]

Within the glargine family, Gla-300 provides additional hypoglycemia reduction over Gla-100:

• EDITION pooled analysis: 31% reduction in nocturnal hypoglycemia, 14% reduction in any-time hypoglycemia [8]
• Benefits most pronounced during the titration phase (first 8 weeks), when hypoglycemia risk is highest

Compared with insulin degludec:

• BRIGHT: Lower hypoglycemia with Gla-300 during titration; comparable over 24 weeks [9]
• CONCLUDE: Primary endpoint not met; numerically lower overall symptomatic hypoglycemia with degludec but not statistically significant [10]

4. Clinical Evidence Summary

5. Dosing in Research

Type 2 Diabetes -- Insulin Initiation (Lantus, U-100). Current guidelines recommend initiating basal insulin at 0.1-0.2 units/kg/day (or a fixed 10 units) administered subcutaneously once daily, typically at bedtime or at a consistent time each day. The dose is titrated every 2-3 days by 2 units (or 10-15%) to achieve a fasting plasma glucose target of 80-130 mg/dL (4.4-7.2 mmol/L). When fasting glucose is closer to target at initiation, the lower starting dose of 0.1 units/kg is appropriate; when substantially above target, 0.2 units/kg is preferred. The injection may be given in the abdomen, thigh, or upper arm, with rotation of injection sites [3].

Type 2 Diabetes -- Toujeo (U-300). Starting dose is 0.2 units/kg/day, with titration every 3-4 days (longer interval than Gla-100 due to extended time to steady state). When switching from Gla-100, the initial Gla-300 dose should be the same number of units, though patients typically require 10-18% higher doses at steady state to achieve equivalent glycemic control [4][5][6][22]. The longer time to steady state (3-5 days vs 2-4 days for Gla-100) necessitates patience during dose titration.

Type 1 Diabetes. Insulin glargine provides the basal component of a basal-bolus regimen. Basal insulin typically constitutes approximately 40-50% of total daily insulin dose. Starting dose is approximately 0.2 units/kg/day (or one-third of total daily dose), with the remainder provided as prandial (rapid-acting) insulin. The same titration principles apply [7][15].

ORIGIN Trial Dosing. Insulin glargine was initiated at 2-10 units once daily at bedtime and titrated weekly to a fasting plasma glucose target of <95 mg/dL (5.3 mmol/L). The median dose at study end was approximately 0.40 units/kg/day [1].

6. Safety and Side Effects

The safety profile of insulin glargine is well-characterized across extensive clinical experience spanning more than two decades and involving millions of patients worldwide.

Hypoglycemia is the most significant adverse effect of any insulin therapy. While insulin glargine has a meaningfully lower risk of hypoglycemia compared with NPH insulin (particularly nocturnal hypoglycemia), the risk is not zero [3][14]. Risk factors include missed meals, excessive exercise, impaired renal or hepatic function, concomitant use of insulin secretagogues or other insulin formulations, and alcohol consumption. Gla-300 offers additional hypoglycemia reduction compared with Gla-100 [8].

Weight gain is an expected consequence of improved glycemic control with insulin therapy. In the ORIGIN trial, insulin glargine was associated with a modest 1.6 kg weight gain over 6.2 years compared with standard care [1]. In clinical practice, weight gain of 1-3 kg is typical in the first year. Insulin detemir may be associated with slightly less weight gain than glargine.

Injection site reactions include lipodystrophy (lipohypertrophy or lipoatrophy) at repeatedly used injection sites, and occasional local erythema, pruritus, or swelling. Proper rotation of injection sites minimizes lipodystrophy risk.

Immunogenicity. Anti-insulin antibodies may develop but are rarely clinically significant. Biosimilar studies (ELEMENT, INSTRIDE) have confirmed similar immunogenicity profiles between reference Lantus and biosimilar products [18][19].

Cancer risk. As extensively discussed in Section 3, the ORIGIN trial (6.2 years) and ORIGINALE follow-up definitively demonstrated no excess cancer risk with insulin glargine. The in vitro concern regarding IGF-1R affinity is not clinically relevant because the parent molecule is rapidly metabolized to M1 and M2, which have human insulin-equivalent mitogenic profiles [1][2][11][12].

Cardiovascular safety. The ORIGIN trial confirmed cardiovascular neutrality, with no excess risk of MACE, heart failure, or cardiovascular death [1][2].

Contraindications. Insulin glargine is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin glargine or any excipient. It should not be administered intravenously or used in insulin infusion pumps, as the microprecipitate mechanism requires subcutaneous administration.

Drug interactions. Drugs that may increase hypoglycemia risk in combination with insulin glargine include sulfonylureas, meglitinides, ACE inhibitors, fibrates, fluoxetine, MAO inhibitors, and pentoxifylline. Drugs that may reduce the glucose-lowering effect include corticosteroids, niacin, diuretics, sympathomimetics, isoniazid, and atypical antipsychotics.

7. Detailed Pharmacokinetics

7.1 Microprecipitate Mechanism and Absorption Kinetics

The pharmacokinetic profile of insulin glargine is entirely governed by its unique physicochemical absorption mechanism [13][16]:

Subcutaneous depot formation. Upon injection of the clear, acidic solution (pH 4.0) into subcutaneous tissue (pH approximately 7.4), the insulin glargine molecules encounter a pH environment near the shifted isoelectric point of 6.7 and rapidly precipitate to form amorphous microprecipitates. These are not crystalline (unlike NPH insulin's protamine-zinc crystals) but rather disordered aggregates that serve as a sustained-release reservoir [13].

Dissolution and absorption. Individual insulin glargine monomers slowly dissolve from the surface of the microprecipitate particles. The rate of dissolution is governed by the surface area of the depot -- a critical pharmacokinetic determinant. Because the dissolution process is gradual, the result is a slow, continuous release of insulin glargine monomers into the systemic circulation [13][16].

7.2 U-100 (Gla-100, Lantus) Pharmacokinetics

• Bioavailability: Approximately 70% relative to intravenous human insulin (subcutaneous route) [13]
• Onset of action: 1-2 hours after injection
• Time to peak effect: No pronounced peak (peakless profile); maximum glucose-lowering effect distributed over approximately 8-16 hours
• Duration of action: Approximately 22-24 hours at steady state, with declining activity toward the end of the 24-hour dosing interval [16]
• Time to steady state: 2-4 days of once-daily dosing
• Within-day variability (CV%): Approximately 40-50% for glucose-lowering effect
• Day-to-day variability (CV%): Approximately 30-40%

7.3 U-300 (Gla-300, Toujeo) Pharmacokinetics

The concentrated formulation (300 U/mL) delivers the same dose in one-third the volume, producing a more compact subcutaneous depot with reduced surface-area-to-volume ratio [16][21][22]:

• Bioavailability: Approximately 70% (similar to Gla-100 per unit of insulin)
• Onset of action: 2-6 hours after injection (delayed vs. Gla-100)
• Time to peak effect: No peak; even flatter profile than Gla-100 with the glucose infusion rate (GIR) profile distributed over a broader interval
• Duration of action: Greater than 30 hours at steady state (vs. approximately 24 hours for Gla-100), with approximately 5 hours of meaningful glucose-lowering activity beyond the 24-hour dosing interval [16]
• Time to steady state: 3-5 days (longer than Gla-100, requiring patience during titration)
• Within-day variability (CV%): Approximately 25-30% (significantly lower than Gla-100) [21]
• Day-to-day variability (CV%): Approximately 20-25% (lower than Gla-100)

The flatter, more extended profile of Gla-300 explains the consistent finding across EDITION trials of reduced nocturnal hypoglycemia compared with Gla-100 at comparable glycemic control [4][5][6][8].

Dose-concentration relationship: Due to the smaller depot surface area, patients switching from Gla-100 to Gla-300 at the same unit dose will initially have lower insulin exposure. The recommended approach is to initiate at the same unit dose but anticipate a need for 10-18% higher doses to achieve equivalent steady-state glucose-lowering effect [8][20][22].

7.4 Metabolite Pharmacokinetics (M1 and M2)

After absorption from the subcutaneous depot, insulin glargine undergoes rapid and extensive enzymatic processing [11][17]:

Metabolic pathway:

1. Parent glargine to M1: Carboxypeptidase enzymes in subcutaneous tissue and circulation cleave the two C-terminal arginine residues (B31-Arg, B32-Arg), yielding 21A-Gly-human insulin (M1)
2. M1 to M2: Further processing removes threonine at position B30, yielding 21A-Gly-des-30B-Thr-human insulin (M2)

Critical finding: At therapeutic doses (0.3-0.6 U/kg), parent insulin glargine is virtually undetectable in the systemic circulation. M1 is the predominant circulating moiety (greater than 90% of measurable insulin-related species), responsible for essentially all of the metabolic glucose-lowering effect [11].

Metabolite pharmacology:

• M1 retains full metabolic potency at the insulin receptor (IR) -- equivalent to human insulin for glucose uptake stimulation, glycogen synthesis, and hepatic glucose output suppression
• M1 has approximately 10-fold lower affinity for the IGF-1 receptor compared to parent glargine, and IGF-1R affinity comparable to native human insulin
• M2 has similar metabolic potency to M1 and similarly low IGF-1R affinity
• The metabolite profile is identical for Gla-100 and Gla-300 (same molecule, same metabolism) [17]

This metabolite pharmacology is the cornerstone of the cancer safety resolution: the molecule with enhanced IGF-1R binding (parent glargine) never reaches the circulation in meaningful quantities [11][12].

7.5 Special Population Pharmacokinetics

• Renal impairment: Insulin clearance is reduced in renal impairment; patients with CKD stages 4-5 frequently require 20-40% dose reduction to avoid hypoglycemia. No specific dose adjustment protocol exists; titrate to fasting glucose.
• Hepatic impairment: Hepatic gluconeogenesis is reduced, and insulin clearance is impaired; patients may require substantially lower doses. Monitor glucose closely.
• Pediatric (age 6+): PK is similar to adults on a weight-adjusted basis. Gla-100 is approved for children aged 6 and older; Gla-300 has limited pediatric data.
• Elderly: Increased hypoglycemia risk due to reduced renal function and impaired counter-regulatory responses; conservative starting doses (0.1 U/kg) and gradual titration recommended.
• Pregnancy: Limited data. Insulin glargine has been used off-label in pregnancy with outcomes similar to NPH in observational studies. Not formally approved for pregnancy in most countries.

8. Dose-Response Relationships

8.1 HbA1c Reduction by Dose and Population

The dose-response relationship for insulin glargine is characterized by a progressive HbA1c reduction with increasing dose, modulated by patient-specific insulin sensitivity:

Type 2 diabetes (insulin-naive) -- typical dose-response:

• Starting dose (0.1-0.2 U/kg/day, or ~10 units): Expected HbA1c reduction of 0.5-0.8% over 12-16 weeks with conservative titration
• Titrated dose (0.3-0.5 U/kg/day, typical range at equilibrium): Expected HbA1c reduction of 1.0-1.5% from baseline (Treat-to-Target trial: 8.6% to 6.96%) [3]
• Higher doses (0.5-1.0 U/kg/day): Achieved in insulin-resistant patients; diminishing marginal HbA1c reduction with increasing dose; hypoglycemia risk increases proportionally
• Very high doses (greater than 1.0 U/kg/day): Suggests severe insulin resistance; consider combination with GLP-1 RA or evaluation for other insulin resistance causes

Type 1 diabetes -- basal dose component:

• Basal insulin typically accounts for 40-50% of total daily dose
• Typical basal dose: 0.15-0.35 U/kg/day
• Adjustments of 1-2 units every 2-3 days based on fasting glucose

ORIGIN trial dose-response [1]:

• Median starting dose: approximately 2-10 units/day
• Median dose at study end (6.2 years): approximately 0.40 U/kg/day
• Mean fasting plasma glucose achieved: 94 mg/dL (target below 95)
• New-onset diabetes reduced by 28% (HR 0.72)

8.2 Fasting Glucose Response to Titration

The Treat-to-Target algorithm [3] provides the best-characterized dose-titration response:

• Fasting glucose above 180 mg/dL: Increase by 6-8 units every 3 days
• Fasting glucose 140-180 mg/dL: Increase by 4 units every 3 days
• Fasting glucose 120-140 mg/dL: Increase by 2 units every 3 days
• Fasting glucose 100-120 mg/dL: Increase by 1-2 units every 3 days
• Fasting glucose 80-100 mg/dL (target range): Maintain dose

Most patients achieve fasting glucose target within 8-16 weeks of titration. The ORIGIN trial demonstrated that aggressive titration to below 95 mg/dL was achievable and safe over 6.2 years [1].

8.3 Hypoglycemia Risk by Dose

Hypoglycemia risk is not linear with dose but accelerates disproportionately as fasting glucose targets approach the lower range:

• Fasting glucose target 100-130 mg/dL: severe hypoglycemia rate approximately 0.5 events per 100 patient-years
• Fasting glucose target 80-100 mg/dL: severe hypoglycemia rate approximately 1.0 events per 100 patient-years (ORIGIN) [1]
• Fasting glucose target below 80 mg/dL: sharply increased risk; not recommended

9. Comparative Effectiveness

9.1 Insulin Glargine vs. NPH Insulin

The Treat-to-Target trial and subsequent meta-analysis provide definitive comparative data [3][14]:

| Outcome | Glargine (Gla-100) | NPH Insulin | Difference | |---------|-------------------|-------------|------------| | HbA1c reduction | -2.4% to ~6.96% | -2.4% to ~6.97% | Equivalent | | Nocturnal hypoglycemia | 33% of patients | 44% of patients | 25% reduction (p = 0.0136) [3] | | Severe hypoglycemia (meta-analysis) | - | - | 46% reduction with glargine [14] | | Severe nocturnal hypoglycemia | - | - | 59% reduction with glargine [14] | | Weight gain (12 weeks) | +2.0 kg | +2.0 kg | Similar | | Dosing frequency | Once daily | Once-twice daily | Advantage glargine | | Injection timing flexibility | Flexible (same time daily) | Bedtime preferred | Advantage glargine |

9.2 Gla-300 (Toujeo) vs. Gla-100 (Lantus)

EDITION pooled analysis (n = 2,496 T2D patients) [8]:

| Outcome | Gla-300 | Gla-100 | Difference | |---------|---------|---------|------------| | HbA1c reduction | Equivalent | Equivalent | Noninferior | | Any-time confirmed hypoglycemia (6 mo) | - | - | 14% lower rate with Gla-300 | | Nocturnal confirmed hypoglycemia (6 mo) | - | - | 31% lower rate with Gla-300 | | Hypoglycemia during titration (0-8 wk) | - | - | Most pronounced benefit for Gla-300 | | Weight gain | -0.7 kg less | Reference | Modest advantage Gla-300 | | Basal insulin dose at equilibrium | 10-18% higher | Reference | Higher dose needed for Gla-300 |

9.3 Insulin Glargine (Gla-300) vs. Insulin Degludec

BRIGHT trial (insulin-naive T2D, n = 929) [9]:

| Outcome | Gla-300 | IDeg-100 | Difference | |---------|---------|----------|------------| | HbA1c reduction (24 wk) | 8.57% to 7.03% | 8.58% to 6.98% | LS mean difference -0.05% (NS) | | Confirmed hypoglycemia (below 54 mg/dL, titration wk 0-12) | 1.1% incidence | 2.4% incidence | Significantly lower with Gla-300 | | Confirmed hypoglycemia (24 wk overall) | 16.8% | 18.4% | Not significant | | Fasting glucose at 24 wk | 108 mg/dL | 105 mg/dL | Not significant | | Weight change | +0.66 kg | +0.77 kg | Not significant |

CONCLUDE trial (insulin-treated T2D at hypoglycemia risk, n = 1,609) [10]:

| Outcome | IDeg-U200 | Gla-300 | Difference | |---------|-----------|---------|------------| | Overall symptomatic hypoglycemia (primary) | - | - | RR 0.88 (NS, p = 0.25) | | Nocturnal symptomatic hypoglycemia | - | - | RR 0.63 (favoring degludec) | | Severe hypoglycemia | - | - | RR 0.20 (favoring degludec) | | Weight change | Greater gain | Reference | More weight gain with degludec |

9.4 Insulin Glargine vs. Insulin Detemir

• Detemir typically requires twice-daily dosing to cover 24 hours (duration 12-24 hours)
• Detemir is associated with slightly less weight gain (~0.5-1.0 kg difference favoring detemir)
• HbA1c reduction is equivalent between agents
• Hypoglycemia rates are comparable between glargine and detemir at equivalent glycemic targets
• Glargine's once-daily dosing offers a convenience advantage

9.5 Summary Positioning

In the current basal insulin landscape:

• NPH insulin: Lowest cost; equivalent HbA1c reduction; significantly more hypoglycemia; appropriate when cost is the primary driver
• Gla-100 (Lantus/biosimilars): First-generation basal analog; once-daily peakless profile; 25-59% less hypoglycemia than NPH; first-choice basal analog in many settings; biosimilars have reduced cost barrier
• Gla-300 (Toujeo): Second-generation formulation; even flatter profile; 14-31% less hypoglycemia than Gla-100; preferred during titration phase when hypoglycemia risk is highest
• Degludec (Tresiba): Ultra-long duration (greater than 42 hours); lowest day-to-day variability; possible nocturnal hypoglycemia advantage in insulin-treated patients; higher cost
• Detemir (Levemir): Often requires twice-daily dosing; modest weight advantage; less commonly used since second-generation analogs became available

10. Enhanced Safety Profile

10.1 Quantitative Adverse Event Rates

| Adverse Event | Gla-100 (Lantus) | Gla-300 (Toujeo) | Notes | |---------------|-----------------|------------------|-------| | Overall hypoglycemia (T2D, 6 mo) | 40-50% of patients | 35-43% of patients | EDITION pooled; 14% rate reduction [8] | | Nocturnal hypoglycemia (T2D, 6 mo) | 20-30% of patients | 14-21% of patients | EDITION pooled; 31% rate reduction [8] | | Severe hypoglycemia (T2D, annual) | 1.0-2.0 per 100 pt-yr | 0.5-1.5 per 100 pt-yr | Lower with Gla-300 | | Severe hypoglycemia (T1D, annual) | 20-30 per 100 pt-yr | 15-25 per 100 pt-yr | Less difference in T1D | | Weight gain (T2D, 6 months) | +0.5 to +1.5 kg | +0.0 to +1.0 kg | Modest advantage Gla-300 | | Weight gain (ORIGIN, 6.2 yr) | +1.6 kg vs. control | - | Minimal long-term | | Injection site lipohypertrophy | 5-10% (chronic use) | 5-10% | Depends on rotation practice | | Anti-insulin antibodies | 20-30% develop | Similar | Rarely clinically significant | | Allergic reactions (local) | 1-2% | 1-2% | Erythema, pruritus | | Allergic reactions (systemic) | Less than 0.1% | Less than 0.1% | Anaphylaxis extremely rare | | Cardiovascular events (ORIGIN) | HR 1.02 (NS) | - | Neutral [1] | | Cancer incidence (ORIGIN) | HR 0.99 (NS) | - | Neutral [1] |

10.2 Drug Interactions

Agents that increase hypoglycemia risk (potentiate glucose lowering):

• Sulfonylureas and meglitinides (pharmacodynamic synergy; most common cause of combined hypoglycemia)
• GLP-1 receptor agonists (when combined with insulin, reduce insulin dose by 10-20%)
• ACE inhibitors (may increase insulin sensitivity)
• Fibrates, fluoxetine, MAO inhibitors, pentoxifylline, salicylates (high doses)
• Alcohol (inhibits hepatic gluconeogenesis)

Agents that reduce glucose-lowering effect (may require insulin dose increase):

• Corticosteroids (potent insulin resistance; may require 20-40% dose increase)
• Thiazide and loop diuretics
• Sympathomimetics (e.g., albuterol, pseudoephedrine)
• Atypical antipsychotics (olanzapine, clozapine -- significant insulin resistance)
• Niacin, isoniazid
• Thyroid hormones
• Estrogens and progestogens (variable effect)

Agents with variable effects:

• Beta-blockers (mask hypoglycemia symptoms; may impair counter-regulation)
• Octreotide/lanreotide (suppress both insulin and glucagon; net effect unpredictable)
• Lithium (may increase or decrease glucose)

10.3 Key Safety Warnings

• Never administer intravenously -- insulin glargine is designed for subcutaneous injection only; the microprecipitate mechanism requires the subcutaneous tissue environment
• Not for use in insulin pumps -- the acidic pH can damage pump components and the microprecipitate mechanism does not function in pump tubing
• Do not dilute or mix with any other insulin or solution
• Refrigerate before first use (2-8 degrees C); once in use, store at room temperature (below 30 degrees C) for up to 28 days (Lantus/biosimilars) or 42 days (Toujeo)
• Never use if cloudy, discolored, or contains particulate matter -- glargine solution should always be clear and colorless

11. Biosimilars and Regulatory Status

United States (FDA).

• April 20, 2000: Lantus (insulin glargine 100 U/mL) approved for type 1 and type 2 diabetes in adults. Subsequently expanded to pediatric patients aged 6 years and older.
• December 16, 2015: Basaglar (insulin glargine, Eli Lilly) approved as a follow-on biologic. It is not designated as interchangeable with Lantus.
• February 25, 2015: Toujeo (insulin glargine 300 U/mL) approved for type 1 and type 2 diabetes in adults, based on the EDITION trial program.
• July 28, 2021: Semglee (insulin glargine-yfgn, Mylan/Biocon) approved as the first interchangeable biosimilar insulin product in the United States. The INSTRIDE switching study demonstrated no clinically meaningful differences when alternating between Semglee and Lantus [19].
• December 2021: Rezvoglar (insulin glargine-aglr, Eli Lilly) approved as a biosimilar; interchangeability designation granted November 2022.

The approval of interchangeable biosimilars has substantially reduced the cost of basal insulin therapy. Branded Lantus pen injectors (5 x 3 mL pens) carry a list price of approximately $345-352, while interchangeable biosimilars (Semglee, Rezvoglar) are available for approximately $98-102.

European Union (EMA). Lantus was approved in 2000 (Optisulin in some markets). Toujeo was approved in 2015. Multiple biosimilars (Abasaglar/Basaglar, Semglee) are approved.

Japan. Lantus and Toujeo are both approved, with additional biosimilar products.

Recent developments (2025-2026):

• Ondibta (insulin glargine biosimilar, Gan & Lee) was authorized for medical use in the European Union in January 2026.
• Semglee discontinuation: Biocon, the manufacturer of Semglee (insulin glargine-yfgn), discontinued Semglee vials and pens effective December 31, 2025, causing market adjustments and shifting patients to alternative biosimilars or Toujeo.
• CalRx Insulin Glargine: California's CalRx program launched insulin glargine pens at $55 for a five-pack of 3 mL pens beginning January 1, 2026, representing a significant public-sector access initiative.
• A 2025 European analysis of 28 countries showed that biosimilar market entry was associated with a median 21.6% price decrease for originator insulin glargine over the preceding decade.

Insulin glargine is manufactured using recombinant DNA technology in Escherichia coli (K12 strain). The manufacturing process involves separate expression of the A and B chains (or expression as a proinsulin precursor), followed by chain combination, folding, enzymatic processing, and chromatographic purification. The final product is formulated as a sterile, clear, colorless solution at pH 4.0, with zinc (30 mcg/mL for Lantus) as a stabilizing excipient. Toujeo uses the same formulation chemistry at three-fold concentration.

12. Related Peptides

See also: Liraglutide (Victoza / Saxenda), Semaglutide (Ozempic / Wegovy), Exenatide (Byetta / Bydureon), Amylin (Pramlintide / Symlin)

13. References

1. [1] ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. (2012). Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. DOI PubMed
2. [2] ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. (2016). Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. DOI PubMed
3. [3] Riddle MC, Rosenstock J, Gerich J, et al. (2003). The Treat-to-Target Trial -- randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. DOI PubMed
4. [4] Riddle MC, Bolli GB, Ziemen M, et al. (2014). New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin (EDITION 1). Diabetes Care. DOI PubMed
5. [5] Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. (2014). New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin (EDITION 2). Diabetes Care. DOI PubMed
6. [6] Bolli GB, Riddle MC, Bergenstal RM, et al. (2015). New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs (EDITION 3). Diabetes Obes Metab. DOI PubMed
7. [7] Home PD, Bergenstal RM, Bolli GB, et al. (2015). New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes (EDITION 4). Diabetes Care. DOI PubMed
8. [8] Ritzel R, Roussel R, Bolli GB, et al. (2015). Patient-level meta-analysis of the EDITION 1, 2, and 3 studies -- glycaemic control and hypoglycaemia with new insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes. Diabetes Obes Metab. DOI PubMed
9. [9] Rosenstock J, Cheng A, Engel SS, et al. (2018). More similarities than differences testing insulin glargine 300 units/mL versus insulin degludec 100 units/mL in insulin-naive type 2 diabetes -- the randomized head-to-head BRIGHT trial. Diabetes Care. DOI PubMed
10. [10] Philis-Tsimikas A, Klonoff DC, Engel SS, et al. (2020). Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes -- the randomised, head-to-head CONCLUDE trial. Diabetologia. DOI PubMed
11. [11] Bolli GB, Hahn AD, Schmidt R, et al. (2012). Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. DOI PubMed
12. [12] Owens DR. (2012). Glargine and cancer -- can we now suggest closure?. Diabetes Care. DOI PubMed
13. [13] Heinemann L, Home PD, Hompesch M. (2019). Differentiating basal insulin preparations -- understanding how they work explains why they are different. Adv Ther. DOI PubMed
14. [14] Mullins P, Sharplin P, Yki-Jarvinen H, et al. (2007). Reduced hypoglycemia risk with insulin glargine -- a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. DOI PubMed
15. [15] Rosenstock J, Park G, Zimmerman J, et al. (2000). Basal insulin glargine versus NPH insulin in patients with type 1 diabetes on multiple daily injections. Diabetes Care. DOI PubMed
16. [16] Becker RH, Dahmen R, Bergmann K, et al. (2015). New insulin glargine 300 units/mL provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/mL. Diabetes Care. DOI PubMed
17. [17] Steinstraesser A, Schmidt R, Bergmann K, et al. (2014). Investigational new insulin glargine 300 U/mL has the same metabolism as insulin glargine 100 U/mL. Diabetes Obes Metab. DOI PubMed
18. [18] Kuerzel GU, Shukla U, Golas HE, et al. (2015). Biosimilar insulin glargine -- the ELEMENT clinical trial programme. Diabetes Obes Metab. DOI PubMed
19. [19] Mylan Inc / Biocon. (2021). Insulin glargine-yfgn (Semglee) switching study -- INSTRIDE. Diabetes Care. PubMed
20. [20] Joshi SR, Joshi S, Gaikwad R, et al. (2023). Comparative clinical efficacy and safety of insulin glargine 300 U/mL (Toujeo) versus insulin glargine 100 U/mL in type 2 diabetes and type 1 diabetes -- a systematic literature review and meta-analysis. Diabetes Obes Metab. DOI PubMed
21. [21] Korsatko S, Deller S, Gla-300 PK Study Group. (2018). Lower pharmacokinetic and pharmacodynamic within-day variability of individual clinical doses of insulin glargine 300 U/mL vs glargine 100 U/mL in T1DM. Diabetes. DOI PubMed
22. [22] Kohn CG, Atchley D, Engel SS. (2016). Insulin glargine 300 U/mL -- a review in diabetes mellitus. Drugs. DOI PubMed
23. [23] Smith U, Gale EAM. (2010). Cancer and diabetes -- are we ready for prime time?. Diabetologia. DOI PubMed
24. [24] Heise T, Nosek L, Bottcher SG, et al. (2012). Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. DOI PubMed
25. [25] Haahr H, Heise T. (2014). A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. DOI PubMed